title: [Is it necessary to continue reporting adverse effects of drugs due to be phased out?].
authors.affiliation: 11, chaussée de la Muette, 75016 Paris, France. Electronic address: revuz.jean@wanadoo.fr.
authors.forename: J
authors.initials: J
authors.lastname: Revuz
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000998:Antiviral Agents / Q000009:adverse effects; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects; D056737:Safety-Based Drug Withdrawals
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir